Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Liabilities and Shareholders Equity (2016 - 2025)

Sangamo Therapeutics has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $59.7 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $59.7 million for Q4 2025, down 41.22% from a year ago — trailing twelve months through Dec 2025 was $332.1 million (down 23.63% YoY), and the annual figure for FY2025 was $59.7 million, down 41.22%.
  • Liabilities and Shareholders Equity for Q4 2025 was $59.7 million at Sangamo Therapeutics, down from $88.6 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for SGMO hit a ceiling of $877.1 million in Q1 2021 and a floor of $59.7 million in Q4 2025.
  • Median Liabilities and Shareholders Equity over the past 5 years was $272.4 million (2023), compared with a mean of $377.6 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 50.12% in 2021 and later plummeted 71.39% in 2024.
  • Sangamo Therapeutics' Liabilities and Shareholders Equity stood at $721.9 million in 2021, then decreased by 22.08% to $562.5 million in 2022, then plummeted by 70.61% to $165.3 million in 2023, then tumbled by 38.52% to $101.6 million in 2024, then crashed by 41.22% to $59.7 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $59.7 million (Q4 2025), $88.6 million (Q3 2025), and $97.6 million (Q2 2025) per Business Quant data.